Improved Therapeutic Results by Pretargeted Radioimmunotherapy of Non–Hodgkin's Lymphoma with a New Recombinant, Trivalent, Anti-CD20, Bispecific Antibody
Open accessPublished version of a preprint
Abstract
We examined whether a pretargeting method using a new recombinant anti-CD20 bispecific antibody (bsMAb) followed by 90Y-1,4,7,10-tetraazacyclododecane-N,N′,N′′,N′′′-tetraacetic acid (90Y-DOTA)-peptide could reduce hematologic toxicity yet improve therapeutic responses compared with conventional 90Y-anti-CD20 IgG and a chemically conjugated bsMAb. TF4, a humanized, tri-Fab bsMAb with two Fabs binding CD20 and one Fab binding histamine-succinyl-glycine (HSG), developed by the dock and lock (DNL) method, was tested in nude mice with Ramos B-cell lymphomas. Optimal pretargeting required a 29-h interval between TF4 and 90Y-DOTA-HSG, and 20-fold more moles of TF4. TF4 cleared more rapidly from the blood than anti-CD20 IgG, with early processing in the liver, spleen, and kidney. At 24 h, TF4 improved tumor uptake of 111In-HSG-peptide 2.6-fold [13% versus 5% injected dose per gram (ID/g)] and enhanced tumor to blood ratios >45-fold (770 versus 17), compared with an anti-CD20 Fab × anti-HSG Fab chemical conjugate, and by 1.6-fold (9.0% versus 5.6% ID/g) and 1,600-fold (522 versus 0.32), respectively, compared with radiolabeled anti-CD20 IgG. A severe (≥90%) and prolonged reduction of WBCs was observed at the maximum dose of 90Y-anti-CD20 IgG, whereas pretargeting resulted in a ≤60% transient drop. TF4 pretargeting resulted in highly significant improvement in survival, curing 33% to 90% of the animals, even at relatively low doses, whereas most tumors progressed quickly without cures with 90Y-anti-CD20 IgG. These results indicate an improved therapeutic index with pretargeted radioimmunotherapy (RAIT) using a DNL-constructed tri-Fab, bsMAb, compared with conventional therapy with directly radiolabeled antibody or with a chemically conjugated bsMAb. These encouraging results prompt testing these constructs for pretargeting RAIT in patients. [Cancer Res 2008;68(13):5282–90]
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
TF4 is a second bsAb built using the DNL method, directed against CD20 for the treatment of NHL.
“TF4 is a second bsAb built using the DNL method, directed against CD20 for the treatment of NHL.”
From Bispecific antibodies for cancer therapy: The light at the end of the tunnel? (2009) · cites this paper as [63]
In xenografted nude mice, TF4 as a pretargeting agent of 111In-HSG-peptide compared with a one-step approach using parental anti-CD20 mAb hA20 directly labeled with 90Y demonstrated a 1,600-fold improvement of tumor-to-blood ratio and a 1.6-fold improvement of tumor uptake.
“Studies performed in xenografted nude mice that compared TF4 as a pretargeting agent of an 111 In-HSG-peptide with a one step approach using the parental anti-CD20 mAb (hA20) directly labeled with 90 Y demonstrated an impressive 1,600-fold improvement of the tumor-to-blood ratio, as well as a 1.6-fold improvement of tumor uptake. 63”
From Bispecific antibodies for cancer therapy: The light at the end of the tunnel? (2009) · cites this paper as [63]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
FcRn: the neonatal Fc receptor comes of age
Roopenian, D. C., & Akilesh, S. (2007) · Nature Reviews Immunology · doi:10.1038/nri2155 · Cited by 2,346 · see citing works
Witzig, T. E., Gordon, L. I., Cabanillas, F., Czuczman, M. S., Emmanouilides, C. E., Joyce, R., Pohlman, B. L., Bartlett, N. L., Wiseman, G. A., Padre, N. M., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.11.076 · Cited by 1,171 · see citing works
131 I-Tositumomab Therapy as Initial Treatment for Follicular Lymphoma
Kaminski, M. S., Tuck, M. K., Estes, J. M., Kolstad, A., Ross, C. W., Zasadny, K. R., Regan, D. D., Kison, P. V., Fisher, S., Kroll, S., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa041511 · Cited by 715 · see citing works
Apoptosis of Malignant Human B Cells by Ligation of CD20 With Monoclonal Antibodies
Shan, D., Ledbetter, J. A., & Press, O. W. (1998) · Blood · doi:10.1182/blood.v91.5.1644 · Cited by 572 · see citing works
Antibody Pretargeting Advances Cancer Radioimmunodetection and Radioimmunotherapy
Goldenberg, D. M., Sharkey, R. M., Paganelli, G., Barbet, J., & Chatal, J. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.8471 · Cited by 350 · see citing works
Self-citationFisher, R. I., Kaminski, M. S., Wahl, R. L., Knox, S. J., Zelenetz, A. D., Vose, J. M., Leonard, J. P., Kroll, S., Goldsmith, S. J., & Coleman, M. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2004.00.9217 · Cited by 240 · see citing works
Axworthy, D. B., Reno, J. M., Hylarides, M. D., Mallett, R. W., Theodore, L. J., Gustavson, L. M., Su, F., Hobson, L. J., Beaumier, P. L., & Fritzberg, A. R. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.4.1802 · Cited by 230 · see citing works
Knox, S. J., Goris, M. L., Tempero, M. A., Weiden, P. L., Gentner, L., Breitz, H. B., Adams, G. P., Axworthy, D. B., Gaffigan, S., Bryan, K., et al. (2000) · PubMed · Cited by 212 · see citing works
Rossi, E. A., Goldenberg, D. M., Cardillo, T. M., McBride, W. J., Sharkey, R. M., & Chang, C.-H. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0600982103 · Cited by 209 · see citing works
Self-citationPerspectives on cancer therapy with radiolabeled monoclonal antibodies.
Sharkey, R. M., & Goldenberg, D. M. (2005) · PubMed · Cited by 200 · see citing works
Self-citationGordon, L. I., Molina, A., Witzig, T. E., Emmanouilides, C. E., Raubtischek, A., Darif, M., Schilder, R. J., Wiseman, G., & White, C. A. (2004) · Blood · doi:10.1182/blood-2003-11-3883 · Cited by 189 · see citing works
Witzig, T. E., Molina, A., Gordon, L. I., Emmanouilides, C. E., Schilder, R. J., Flinn, I. W., Darif, M., Macklis, R. M., Vo, K., & Wiseman, G. A. (2007) · Cancer · doi:10.1002/cncr.22617 · Cited by 176 · see citing works
Stein, R., Qu, Z., Chen, S. E., Rosario, A., Shi, V., Hayes, M. K., Horak, I. D., Hansen, H. J., & Goldenberg, D. M. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0493 · Cited by 171 · see citing works
Self-citationForero, A., Weiden, P. L., Vose, J. M., Knox, S. J., LoBuglio, A. F., Hankins, J. H., Goris, M. L., Picozzi, V. J., Axworthy, D. B., Breitz, H. B., et al. (2004) · Blood · doi:10.1182/blood-2003-09-3284 · Cited by 155 · see citing works
Doussal, J. M. L., Martin, M., Gautherot, E., DELAAGE, M. A., & Barbet, J. (1989) · PubMed · Cited by 153 · see citing works
The Radioisotope Contributes Significantly to the Activity of Radioimmunotherapy
Davis, T. A., Kaminski, M. S., Leonard, J. P., Hsu, F. J., Wilkinson, M. J., Zelenetz, A. D., Wahl, R. L., Kroll, S., Coleman, M., Goris, M. L., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0756 · Cited by 152 · see citing works
Press, O. W., Corcoran, M. C., Subbiah, K., Hamlin, D. K., Wilbur, D. S., Johnson, T., Theodore, L. J., Yau, E. K. C., Mallett, R. W., Meyer, D. L., et al. (2001) · Blood · doi:10.1182/blood.v98.8.2535 · Cited by 148 · see citing works
Czuczman, M. S., Emmanouilides, C. E., Darif, M., Witzig, T. E., Gordon, L. I., Revell, S., Vo, K., & Molina, A. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.2882 · Cited by 145 · see citing works
Gordon, L. I., Witzig, T. E., Molina, A., Czuczman, M. S., Emmanouilides, C. E., Joyce, R., Vo, K., Theuer, C. P., Pohlman, B. L., Bartlett, N. L., et al. (2004) · Clinical Lymphoma · doi:10.3816/clm.2004.n.015 · Cited by 124 · see citing works
Improving the Delivery of Radionuclides for Imaging and Therapy of Cancer Using Pretargeting Methods
Sharkey, R. M., Karacay, H., Cardillo, T. M., Chang, C., McBride, W. J., Rossi, E. A., Horak, I. D., & Goldenberg, D. M. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-1004-0009 · Cited by 121 · see citing works
Self-citationBispecific antibody pretargeting PET (immunoPET) with an 124I-labeled hapten-peptide.
McBride, W. J., ZANZONICO, P. B., Sharkey, R. M., Norén, C., Karacay, H., Rossi, E. A., Losman, M. J., Brard, P.-Y., Chang, C., Larson, S. M., et al. (2006) · PubMed · Cited by 111 · see citing works
Self-citationB-cell targeted therapies in rheumatoid arthritis and systemic lupus erythematosus
Eisenberg, R. A., & Albert, D. (2006) · Nature Clinical Practice Rheumatology · doi:10.1038/ncprheum0042 · Cited by 103 · see citing works
Kaminski, M. S., Radford, J. A., Gregory, S. A., Leonard, J. P., Knox, S. J., Kroll, S., & Wahl, R. L. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.0892 · Cited by 95 · see citing works
Wiseman, G. A., & Witzig, T. E. (2005) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.2005.20.185 · Cited by 86 · see citing works
Emmanouilides, C. E., Witzig, T. E., Gordon, L. I., Vo, K., Wiseman, G. A., Flinn, I. W., Darif, M., Schilder, R. J., & Molina, A. (2006) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428190500376076 · Cited by 85 · see citing works
The emerging role of rituximab in organ transplantation
Becker, Y. T., Samaniego, M., & Sollinger, H. W. (2006) · Transplant International · doi:10.1111/j.1432-2277.2006.00345.x · Cited by 78 · see citing works
Chang, C., Rossi, E. A., & Goldenberg, D. M. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1217 · Cited by 78 · see citing works
Self-citationGautherot, E., Rouvier, É., Daniel, L., Loucif, E., Bouhou, J., Manetti, C., Martin, M., Doussal, J. M. L., & Barbet, J. (2000) · PubMed · Cited by 75 · see citing works
Zhang, N., Khawli, L. A., Hu, P., & Epstein, A. L. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0554 · Cited by 71 · see citing works
Subbiah, K., Hamlin, D. K., Pagel, J. M., Wilbur, D. S., Meyer, D. L., Axworthy, D. B., Mallett, R. W., Theodore, L. J., Stayton, P. S., & Press, O. W. (2003) · PubMed · Cited by 67 · see citing works
Novel radiolabeled antibody conjugates
Goldenberg, D. M., & Sharkey, R. M. (2007) · Oncogene · doi:10.1038/sj.onc.1210373 · Cited by 63 · see citing works
Self-citationKaracay, H., Brard, P.-Y., Sharkey, R. M., Chang, C., Rossi, E. A., McBride, W. J., Ragland, D. R., Horak, I. D., & Goldenberg, D. M. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1246 · Cited by 58 · see citing works
Self-citationCheung, N. V., Modak, S. I., Lin, Y., Guo, H.-F., ZANZONICO, P. B., Chung, J., Zuo, Y., Sanderson, J., Wilbert, S. M., Theodore, L. J., et al. (2004) · PubMed · Cited by 56 · see citing works
Graves, S. S., Dearstyne, E., Lin, Y., Zuo, Y., Sanderson, J., Schultz, J., Pantalias, A., Gray, D., Axworthy, D. B., Jones, H. M., et al. (2003) · PubMed · Cited by 53 · see citing works
Sharkey, R. M., Karacay, H., Chang, C., McBride, W. J., Horak, I. D., & Goldenberg, D. M. (2005) · Leukemia · doi:10.1038/sj.leu.2403751 · Cited by 52 · see citing works
Self-citationOptimizing bispecific antibody pretargeting for use in radioimmunotherapy.
Sharkey, R. M., Karacay, H., Richel, H., McBride, W. J., Rossi, E. A., Chang, K., Yeldell, D., Griffiths, G. L., Hansen, H. J., & Goldenberg, D. M. (2003) · PubMed · Cited by 51 · see citing works
Self-citationMonoclonal Antibody Therapy for B-Cell Malignancies
Cheson, B. D. (2006) · Seminars in Oncology · doi:10.1053/j.seminoncol.2006.01.024 · Cited by 51 · see citing works
Pagel, J. M., Lin, Y., Hedin, N., Pantelias, A., Axworthy, D. B., Stone, D. M., Hamlin, D. K., Wilbur, D. S., & Press, O. W. (2006) · Blood · doi:10.1182/blood-2005-11-4327 · Cited by 47 · see citing works
Safety and Efficacy of Yttrium-90 Ibritumomab Tiuxetan in Older Patients With Non-Hodgkin's Lymphoma
Emmanouilides, C. E., Witzig, T. E., Wiseman, G. A., Gordon, L. I., Wang, H., Schilder, R. J., Saville, M. W., Flinn, I. W., & Molina, A. (2007) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.2007.359 · Cited by 46 · see citing works
Apoptosis of Malignant Human B Cells by Ligation of CD20 With Monoclonal Antibodies
Shan, D., Ledbetter, J. A., & Press, O. W. (1998) · Blood · doi:10.1182/blood.v91.5.1644.1644_1644_1652 · Cited by 45 · see citing works
Evaluation of CD20, CD22, and HLA-DR Targeting for Radioimmunotherapy of B-Cell Lymphomas
Pagel, J. M., Pantelias, A., Hedin, N., Wilbur, S. M., Saganic, L., Lin, Y., Axworthy, D. B., Hamlin, D. K., Wilbur, D. S., Gopal, A. K., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-0080 · Cited by 43 · see citing works
B-cell targeting: a novel approach to immune intervention today and tomorrow
Dörner, T., & Lipsky, P. E. (2007) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.7.9.1287 · Cited by 38 · see citing works
Hagenbeek, A., Bischof-Delaloye, A., Radford, J. A., Rohatiner, A. Z. S., Salles, G., Hoof, A. V., Pütz, B., Kunz, M., & Morschhauser, F. (2007) · Blood · doi:10.1182/blood.v110.11.643.643 · Cited by 35 · see citing works
Pagel, J. M., Hedin, N., Drouet, L., Wood, B. L., Pantelias, A., Lin, Y., Hamlin, D. K., Wilbur, D. S., Gopal, A. K., Green, D. J., et al. (2007) · Blood · doi:10.1182/blood-2007-06-097451 · Cited by 33 · see citing works
Radioimmunotherapy of non-Hodgkin’s lymphoma: a critical appraisal
Sharkey, R. M., Burton, J., & Goldenberg, D. M. (2005) · Expert Review of Clinical Immunology · doi:10.1586/1744666x.1.1.47 · Cited by 33 · see citing works
Self-citationMichel, R. B., Ochakovskaya, R., & Mattes, M. J. (2002) · PubMed · Cited by 23 · see citing works
The expanding role of rituximab and radioimmunotherapy in the treatment of B-cell lymphomas
Jacobs, S. A., & Foon, K. A. (2007) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.7.11.1749 · Cited by 8 · see citing works
Targeted Therapies for Non-Hodgkin Lymphoma: Rationally Designed Combinations
Martin, P., & Leonard, J. P. (2007) · Clinical Lymphoma & Myeloma · doi:10.3816/clm.2007.s.022 · Cited by 5 · see citing works
Brard, P.-Y., Karacay, H., Stein, R., Sharkey, R. M., Mattes, M. J., Chang, C., Rossi, E. A., McBride, W. J., & Goldenberg, D. M. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1204 · Cited by 2 · see citing works
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
The making of bispecific antibodies
Brinkmann, U., & Kontermann, R. E. (2017) · mAbs · doi:10.1080/19420862.2016.1268307 · Cited by 933 · see citing works
A Novel Method of 18F Radiolabeling for PET
McBride, W. J., Sharkey, R. M., Karacay, H., D'Souza, C. A., Rossi, E. A., Laverman, P., Chang, C., Boerman, O. C., & Goldenberg, D. M. (2009) · Journal of Nuclear Medicine · doi:10.2967/jnumed.108.060418 · Cited by 419 · see citing works
Self-citationBispecific antibodies for cancer therapy: The light at the end of the tunnel?
Chames, P., & Baty, D. (2009) · mAbs · doi:10.4161/mabs.1.6.10015 · Cited by 336 · see citing works
Improved 18 F Labeling of Peptides with a Fluoride-Aluminum-Chelate Complex
McBride, W. J., D'Souza, C. A., Sharkey, R. M., Karacay, H., Rossi, E. A., Chang, C., & Goldenberg, D. M. (2010) · Bioconjugate Chemistry · doi:10.1021/bc100137x · Cited by 200 · see citing works
Self-citationAghevlian, S., Boyle, A. J., & Reilly, R. M. (2015) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.12.003 · Cited by 194 · see citing works
Multivalent antibodies: when design surpasses evolution
Cuesta, Á. M., Sainz-Pastor, N., Bonet, J., Oliva, B., & Álvarez‐Vallina, L. (2010) · Trends in biotechnology · doi:10.1016/j.tibtech.2010.03.007 · Cited by 186 · see citing works
Rossin, R., Läppchen, T., van den Bosch, S. M., Laforest, R. A., & Robillard, M. S. (2013) · Journal of Nuclear Medicine · doi:10.2967/jnumed.113.123745 · Cited by 184 · see citing works
Grading the commercial optical biosensor literature—Class of 2008: ‘The Mighty Binders’
Rich, R. L., & Myszka, D. G. (2009) · Journal of Molecular Recognition · doi:10.1002/jmr.1004 · Cited by 167 · see citing works
Sharkey, R. M., & Goldenberg, D. M. (2011) · Immunotherapy · doi:10.2217/imt.10.114 · Cited by 136 · see citing works
Self-citationPretargeted Molecular Imaging and Radioimmunotherapy
Goldenberg, D. M., Chang, C., Rossi, E. A., McBride, W. J., & Sharkey, R. M. (2012) · Theranostics · doi:10.7150/thno.3582 · Cited by 108 · see citing works
Self-citationAntibody Positron Emission Tomography Imaging in Anticancer Drug Development
Lamberts, L. E., Williams, S. P., van Scheltinga, A. G. T. T., Hooge, M. N. L., Schröder, C. P., Gietema, J. A., Brouwers, A. H., & de Vries, E. G. E. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.57.8278 · Cited by 104 · see citing works
A modular IgG-scFv bispecific antibody topology
Orcutt, K. D., Ackerman, M. E., Cieslewicz, M., Quiroz, E., Slusarczyk, A. L., Frangioni, J. V., & Wittrup, K. D. (2009) · Protein Engineering Design and Selection · doi:10.1093/protein/gzp077 · Cited by 101 · see citing works
Pretargeting: A Path Forward for Radioimmunotherapy
Cheal, S. M., Chung, S. K., Vaughn, B. A., Cheung, N. V., & Larson, S. M. (2022) · Journal of Nuclear Medicine · doi:10.2967/jnumed.121.262186 · Cited by 96 · see citing works
Schoffelen, R., Boerman, O. C., Goldenberg, D. M., Sharkey, R. M., van Herpen, C. M. L., Franssen, G. M., McBride, W. J., Chang, C.-H., Rossi, E. A., van der Graaf, W. T. A., et al. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.376 · Cited by 90 · see citing works
Self-citationSharkey, R. M., Rossi, E. A., McBride, W. J., Chang, C., & Goldenberg, D. M. (2010) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2009.12.002 · Cited by 77 · see citing works
Self-citationCoiled-coil based drug-free macromolecular therapeutics: In vivo efficacy
Wu, K., Yang, J., Liu, J., & Kopec̆ek, J. (2011) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.08.002 · Cited by 77 · see citing works
Pretargeted Imaging and Radioimmunotherapy of Cancer Using Antibodies and Bioorthogonal Chemistry
van de Watering, F. C. J., Rijpkema, M., Robillard, M. S., Oyen, W. J. G., & Boerman, O. C. (2014) · Frontiers in Medicine · doi:10.3389/fmed.2014.00044 · Cited by 72 · see citing works
Sharkey, R. M., Press, O. W., & Goldenberg, D. M. (2009) · Blood · doi:10.1182/blood-2008-11-188896 · Cited by 71 · see citing works
Self-citationKawashima, H. (2014) · The Scientific World JOURNAL · doi:10.1155/2014/492061 · Cited by 71 · see citing works
Therapeutic Applications of Pretargeting
Verhoeven, M., Seimbille, Y., & Dalm, S. U. (2019) · Pharmaceutics · doi:10.3390/pharmaceutics11090434 · Cited by 64 · see citing works
Endoradiotherapy in cancer treatment — Basic concepts and future trends
Zoller, F., Eisenhut, M., Haberkorn, U., & Mier, W. (2009) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2009.05.035 · Cited by 60 · see citing works
Carrier systems of radiopharmaceuticals and the application in cancer therapy
Zhang, T., Lei, H., Chen, X., Dou, Z., Yu, B., Su, W., Wang, W., Jin, X., Katsube, T., Wang, B., et al. (2024) · Cell Death Discovery · doi:10.1038/s41420-023-01778-3 · Cited by 58 · see citing works
New Antibody Conjugates in Cancer Therapy
Govindan, S. V., & Goldenberg, D. M. (2010) · The Scientific World JOURNAL · doi:10.1100/tsw.2010.191 · Cited by 56 · see citing works
Self-citationSharkey, R. M., Karacay, H., Johnson, C. R., Litwin, S., Rossi, E. A., McBride, W. J., Chang, C., & Goldenberg, D. M. (2009) · Journal of Nuclear Medicine · doi:10.2967/jnumed.108.058602 · Cited by 56 · see citing works
Self-citationKumar, K., & Ghosh, A. K. (2018) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.7b00817 · Cited by 56 · see citing works
Pagel, J. M., Orgun, N. N., Hamlin, D. K., Wilbur, D. S., Gooley, T. A., Gopal, A. K., Park, S. I., Green, D. J., Lin, Y., & Press, O. W. (2009) · Blood · doi:10.1182/blood-2008-11-187401 · Cited by 56 · see citing works
A Preclinical Model of CD38-Pretargeted Radioimmunotherapy for Plasma Cell Malignancies
Green, D. J., Orgun, N. N., Jones, J. C., Hylarides, M. D., Pagel, J. M., Hamlin, D. K., Wilbur, D. S., Lin, Y., Fisher, D. R., Kenoyer, A. L., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-1589 · Cited by 55 · see citing works
Natarajan, A., Hackel, B. J., & Gambhir, S. S. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0626 · Cited by 54 · see citing works
Schoffelen, R., van der Graaf, W. T. A., Franssen, G. M., Sharkey, R. M., Goldenberg, D. M., McBride, W. J., Rossi, E. A., Eek, A., Oyen, W. J. G., & Boerman, O. C. (2010) · Journal of Nuclear Medicine · doi:10.2967/jnumed.110.079376 · Cited by 50 · see citing works
Self-citationRossi, E. A., Goldenberg, D. M., & Chang, C. (2011) · Bioconjugate Chemistry · doi:10.1021/bc2004999 · Cited by 49 · see citing works
Self-citationVelikyan, I. (2018) · Contrast Media & Molecular Imaging · doi:10.1155/2018/9713691 · Cited by 49 · see citing works
Karacay, H., Sharkey, R. M., Gold, D. V., Ragland, D. R., McBride, W. J., Rossi, E. A., Chang, C., & Goldenberg, D. M. (2009) · Journal of Nuclear Medicine · doi:10.2967/jnumed.109.067686 · Cited by 48 · see citing works
Self-citationSchoffelen, R., der Weg, W. W.-V., Visser, E. P., Goldenberg, D. M., Sharkey, R. M., McBride, W. J., Chang, C., Rossi, E. A., van der Graaf, W. T. A., Oyen, W. J. G., et al. (2014) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-014-2742-6 · Cited by 41 · see citing works
Self-citationBispecific Antibodies for Cancer Therapy
Hollander, N. (2009) · Immunotherapy · doi:10.2217/1750743x.1.2.211 · Cited by 38 · see citing works
Radioimmunotherapy of B-cell non-Hodgkin’s lymphoma
Bodet‐Milin, C. (2013) · Frontiers in Oncology · doi:10.3389/fonc.2013.00177 · Cited by 36 · see citing works
Pretargeting: taking an alternate route for localizing radionuclides
Sharkey, R. M., Chang, C., Rossi, E. A., McBride, W. J., & Goldenberg, D. M. (2012) · Tumor Biology · doi:10.1007/s13277-012-0367-6 · Cited by 33 · see citing works
Self-citationHo, K., Liu, Y.-L., Liao, T.-Y., Liu, E.-S., & Cheng, T.-L. (2024) · International Journal of Nanomedicine · doi:10.2147/ijn.s479270 · Cited by 32 · see citing works
Pretargeted Radioimmunotherapy for Hematologic and Other Malignancies
Walter, R. B., Press, O. W., & Pagel, J. M. (2010) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.2010.0759 · Cited by 31 · see citing works
Yang, Q., Parker, C. L., McCallen, J., & Lai, S. K. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.09.040 · Cited by 31 · see citing works
Engineering Antibodies for Cancer Therapy
Boder, E. T., & Jiang, W. (2011) · Annual Review of Chemical and Biomolecular Engineering · doi:10.1146/annurev-chembioeng-061010-114142 · Cited by 31 · see citing works
Frampas, É., Maurel, C., Saëc, P. L., Mauxion, T., Faivre-Chauvet, A., Davodeau, F., Goldenberg, D. M., Bardiès, M., & Barbet, J. (2011) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-011-1903-0 · Cited by 29 · see citing works
Self-citationA pretargeted nanoparticle system for tumor celllabeling
Gunn, J., Park, S. I., Omid Veiseh, A., Press, O. W., & Zhang, M. (2010) · Molecular BioSystems · doi:10.1039/c005154c · Cited by 29 · see citing works
Radionuclides for Imaging and Therapy in Oncology
Velikyan, I. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-407722-5.00017-7 · Cited by 26 · see citing works
Wang, T., Kievit, F. M., Omid Veiseh, A., Arami, H., Stephen, Z. R., Fang, C., Liu, Y., Ellenbogen, R. G., & Zhang, M. (2013) · World Neurosurgery · doi:10.1016/j.wneu.2013.01.011 · Cited by 26 · see citing works
Pagel, J. M., Matthews, D. C., Kenoyer, A. L., Hamlin, D. K., Wilbur, D. S., Fisher, D. R., Gopal, A. K., Lin, Y., Saganic, L., Appelbaum, F. R., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-2513 · Cited by 25 · see citing works
Improved Cancer Therapy and Molecular Imaging with Multivalent, Multispecific Antibodies
Sharkey, R. M., Rossi, E. A., Chang, C., & Goldenberg, D. M. (2010) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.2009.0690 · Cited by 22 · see citing works
Self-citationImproving the treatment of non‐Hodgkin lymphoma with antibody‐targeted radionuclides
Sharkey, R. M., Karacay, H., & Goldenberg, D. M. (2010) · Cancer · doi:10.1002/cncr.24802 · Cited by 21 · see citing works
Self-citationUsing antibodies to target cancer therapeutics
Goldenberg, D. M., & Sharkey, R. M. (2012) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2012.693472 · Cited by 21 · see citing works
Self-citationRadioimmunotherapy of Non-Hodgkin B-cell Lymphoma: An update
Cicone, F., Santo, G., Bodet‐Milin, C., Cascini, G. L., Kraeber‐Bodéré, F., Stokke, C., & Kolstad, A. (2023) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2022.12.006 · Cited by 19 · see citing works
Complex and defined biostructures with the dock-and-lock method
Rossi, E. A., Goldenberg, D. M., & Chang, C. (2012) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2012.06.001 · Cited by 18 · see citing works
Self-citationRecent preclinical and clinical advances in radioimmunotherapy for non-Hodgkin’s lymphoma
Goto, H., Shiraishi, Y., & Okada, S. (2024) · Exploration of Targeted Anti-tumor Therapy · doi:10.37349/etat.2024.00213 · Cited by 17 · see citing works
CD20-targeting in B-cell malignancies: novel prospects for antibodies and combination therapies
Safdari, Y., Ahmadzadeh, V., & Farajnia, S. (2016) · Investigational New Drugs · doi:10.1007/s10637-016-0349-4 · Cited by 15 · see citing works
Ueda, M., Kudo, T., Kuge, Y., Mukai, T., Tanaka, S., Konishi, H., Miyano, A., Ono, M., Kizaka‐Kondoh, S., Hiraoka, M., et al. (2010) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-010-1467-4 · Cited by 14 · see citing works
Radioactive Antibodies: A Historical Review of Selective Targeting and Treatment of Cancer
Goldenberg, D. M., & Sharkey, R. M. (2010) · Hospital Practice · doi:10.3810/hp.2010.06.300 · Cited by 13 · see citing works
Self-citationThe Diversity of 68Ga-Based Imaging Agents
Velikyan, I. (2012) · Recent results in cancer research/Recent Results in Cancer Research · doi:10.1007/978-3-642-27994-2_7 · Cited by 12 · see citing works
Rossi, D. L., Rossi, E. A., Goldenberg, D. M., & Chang, C. (2011) · Biotechnology Progress · doi:10.1002/btpr.584 · Cited by 11 · see citing works
Self-citationStröhlein, M. A., & Heiss, M. M. (2012) · Der Onkologe · doi:10.1007/s00761-012-2287-x · Cited by 10 · see citing works
Elekonawo, F. M. K., Lütje, S., Franssen, G. M., Bos, D. L., Goldenberg, D. M., Boerman, O. C., & Rijpkema, M. (2019) · EJNMMI Research · doi:10.1186/s13550-019-0551-4 · Cited by 9 · see citing works
Self-citationContinuing progress in radioimmunotherapy for hematologic malignancies
Goto, H., Shiraishi, Y., & Okada, S. (2024) · Blood Reviews · doi:10.1016/j.blre.2024.101250 · Cited by 5 · see citing works
Characteristics of Ibritumomab as Radionuclide Therapy Agent
Kawashima, H. (2018) · Resistance to targeted anti-cancer therapeutics · doi:10.1007/978-3-319-78238-6_6 · Cited by 5 · see citing works
Pretargeted Radioimmunotherapy of Cancer
Sharkey, R. M., & Goldenberg, D. M. (2010) · doi:10.1002/9780470613214.ch8 · Cited by 5 · see citing works
Self-citationNovel Methods to Improve the Efficiency of Radioimmunotherapy for Non-Hodgkin Lymphoma
Eskian, M., Khorasanizadeh, M., Zinzani, P. L., Illidge, T., & Rezaei, N. (2019) · International Reviews of Immunology · doi:10.1080/08830185.2019.1588266 · Cited by 4 · see citing works
Immunoconjugate Anticancer Therapeutics
Govindan, S. V., & Goldenberg, D. M. (2009) · Springer eBooks · doi:10.1007/978-1-4419-0507-9_10 · Cited by 4 · see citing works
Self-citationHost–guest Architectures: Advancing pretargeting strategies for precision theranostics
Gan, J., Yu, Y., Li, Y., Wu, D., & Yu, G. (2025) · Precision medicine and engineering. · doi:10.1016/j.preme.2025.100035 · Cited by 3 · see citing works
CD38 pretargeted RIT of B-cell tumors
Buchsbaum, D. J. (2018) · Blood · doi:10.1182/blood-2017-12-819011 · Cited by 2 · see citing works
Radioimmunotherapy in Metastatic Colorectal Cancer
Meller, J., Liersch, T., Meller, B., Homayounfar, K., & Sahlmann, C. (2012) · Medical radiology · doi:10.1007/174_2012_680 · Cited by 2 · see citing works
Radionuclides for imaging and therapy in oncology
Velikyan, I. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-22253-5.00026-1 · Cited by 1 · see citing works
Radioimmunotherapy of Tumors: Pretargeting with Bispecific Antibodies
Sharkey, R. M., & Goldenberg, D. M. (2012) · Medical radiology · doi:10.1007/174_2012_679 · Cited by 1 · see citing works
Self-citationKo, A., Shatik, S. V., & Самойлович, М. П. (2024) · Siberian Journal of Oncology · doi:10.21294/1814-4861-2024-23-4-162-171 · Cited by 1 · see citing works
Imaging of Hypoxia-Inducible Factor-1-Active Regions in Tumors Using a POS and 123I-IBB Method
Ueda, M., & Saji, H. (2011) · Springer eBooks · doi:10.1007/978-94-007-2019-0_15
Bifunctional Antibodies: Preclinical and Clinical Applications
Shuptrine, C. W., & Weiner, L. M. (2013) · Springer eBooks · doi:10.1007/978-1-4614-8809-5_10
Resistance to Y-90 Ibritumomab Tiuxetan Therapy
Abe, K. (2018) · Resistance to targeted anti-cancer therapeutics · doi:10.1007/978-3-319-78238-6_3
Walsh, J. H. (2019) · CUNY Academic Works (City University of New York)
Pretargeting: Advancing the Delivery of Radionuclides
Sharkey, R. M., & Goldenberg, D. M. (2012) · Springer eBooks · doi:10.1007/978-1-4614-4021-5_20
Self-citation
- Authors
- Sharkey, R. M., Karacay, H., Litwin, S., Rossi, E. A., McBride, W. J., Chang, C.-H., & Goldenberg, D. M.
- Affiliations
- Center for Molecular Medicine and Immunology (US)
- Fox Chase Cancer Center (US)
- 3IBC Pharmaceuticals, Inc.;
- Immunomedics (United States) (US)
- Venue
- Cancer Research
- Published
- 2008-07-01
- Volume
- 68
- Issue
- 13
- Pages
- 5282-5290
- ISSN
- 0008-5472 (ISSN-L)
- 1538-7445
- PMC
- PMC2585743
- OpenAlex
- W2138994942
- Cited by
- 75
- References
- 49
- Citations by year
- 2025: 2 · 2024: 5 · 2023: 1 · 2022: 1 · 2019: 4 · 2018: 5 · 2017: 1 · 2016: 1 · 2015: 4 · 2014: 4 · 2013: 7 · 2012: 9
- FWCI
- 7.93
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Cancer Research (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health
- ImmunoMedics
- National Cancer Institute (P01CA103985)
- Topics
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Radiopharmaceutical Chemistry and Applications
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Monoclonal and Polyclonal Antibodies Research
- Health Sciences › Medicine › Pathology and Forensic Medicine › Lymphoma Diagnosis and Treatment
- Keywords
- pretargeted radioimmunotherapy, non-Hodgkin lymphoma, tumor-to-blood ratio, hematologic toxicity, therapeutic index, B-cell lymphoma
- MeSH terms
- Animals, Biological Availability, Female, Humans, Lymphoma, Non-Hodgkin, Mice, Inbred BALB C, Mice, Nude, Models, Biological, Recombinant Fusion Proteins, Tissue Distribution, Tumor Cells, Cultured, Radioimmunotherapy, Drug Delivery Systems, Treatment Outcome, Antibodies, Bispecific, Immunoconjugates, Antigens, CD20, Xenograft Model Antitumor Assays, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
